The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries

Overview of attention for article published in Advances in Therapy, April 2017

Altmetric Badge

About this Attention Score

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 2,096 followers.

RT @AnnemarieVtW: #Rituximab #Biosimilar CT-P10 in Rheumatology & Cancer: Budget Impact Analysis in 28 European Countries #biosimilars http…

László Gulács et al analyse the budget impact of #rituximab #biosimilar CT-P10 in rheumatology and cancer https://t.co/mh6qqj0dmd